Skip to main content
NewslettersWatchlist

Roche Holdings Ltd ADR(RHHBY)
OTC US

Today's Change
Delayed Last Update
Day Low37.5000
Day High37.8100
Open:37.6900
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Motley Fool
3 Top Stocks That Could Still Rocket Higher in 2024
Barchart
3 Unusually Active Options to Play America’s Most Undervalued Stocks
Motley Fool
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Motley Fool
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
Motley Fool
Why Roche Holdings Stock Withered on Wednesday
Yolowire
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives
Motley Fool
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
Motley Fool
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
Newswire.ca
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates
BayStreet.ca
Biotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient Outcomes
Motley Fool
Here's Why Eli Lilly Stock Dropped 12% Last Month
Motley Fool
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
Newswire.ca
Exploring New Frontiers in Food Allergy Treatments: Market Set for $14B Growth
Motley Fool
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Motley Fool
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Motley Fool
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Motley Fool
This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?
Motley Fool
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
Motley Fool
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
Business Wire
Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)
GlobeNewswire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
Newswire.ca
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments

Profile

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.